A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Trial Profile

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Renal cell carcinoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Epizyme
  • Most Recent Events

    • 04 Aug 2017 According to an Epizyme media release, the company completed enrollment in the epithelioid sarcoma (ES) cohort in Jul 2017.
    • 02 Jun 2017 Results (n=33) aseessing safety and efficacy in patients with synovial sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Preliminary results (n=31) aseessing safety and efficacy in patients with INI1 negative epithelioid sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top